Pulse Biosciences, Inc. (PLSE) – Company Press Releases
-
Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024
-
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results
-
Pulse Biosciences Announces Plans to Initiate a Rights Offering
-
Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024
-
Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System
-
Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study
-
Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium
-
Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX® nsPFA™ Cardiac Clamp
-
Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX™ Nanosecond Pulsed Field Ablation (nsPFA™) Cardiac Catheter
-
Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX nsPFA Percutaneous Electrode
-
Pulse Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference
-
Pulse Biosciences Reports Business Updates and Third Quarter 2023 Financial Results
-
UPDATE Pulse Biosciences Announces New Time for Third Quarter 2023 Financial Results Conference Call
-
Pulse Biosciences Schedules Third Quarter 2023 Financial Results Conference Call for November 13, 2023
-
Pulse Biosciences Appoints Dr. Niv Ad as Chief Science Officer, Cardiac Surgery
-
Pulse Biosciences Announces Collaboration with CardioNXT for nsPFA First-in-Human Atrial Fibrillation Study
-
Pulse Biosciences’ Nanosecond Pulsed Field Ablation (nsPFA™) Circumferential Catheter System to be Featured in a Presentation at the Global EP Summit
-
Pulse Biosciences’ First Study in a Surgical Application of Nanosecond Pulsed Field Ablation (nsPFA) Technology to be Featured in Two Poster Presentations at the American Thyroid Association Annual
-
Pulse Biosciences to Present at Gilmartin Group Emerging Growth Showcase
-
Pulse Biosciences Clarifies Details of Recent S-3 Filing
-
Pulse Biosciences Reports Business Updates and Second Quarter 2023 Financial Results
-
Pulse Biosciences Schedules Second Quarter 2023 Financial Results Conference Call for August 10, 2023
-
Pulse Biosciences’ Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm 2023 Annual Meeting
-
Pulse Biosciences Reports Business Updates and First Quarter 2023 Financial Results
-
Pulse Biosciences, Inc. Announces Planned Redemption of Warrants
-
Pulse Biosciences Announces $65 Million Private Placement
-
Pulse Biosciences Schedules First Quarter 2023 Financial Results Conference Call for May 11, 2023
-
Pulse Biosciences Reports Fourth Quarter & Full Year 2022 Financial Results
-
Pulse Biosciences Schedules Fourth Quarter & Full Year 2022 Financial Results Conference Call for March 30, 2023
-
Pulse Biosciences Announces Its Novel Nanosecond Pulsed Field Ablation System Will Be Highlighted at the 2023 AF Symposium
-
Pulse Biosciences Reports Third Quarter 2022 Financial Results
-
Pulse Biosciences Schedules Third Quarter 2022 Financial Results Conference Call for November 10, 2022
-
Pulse Biosciences Announces Positive Clinical Data on Nano-Pulse Stimulation Procedure for Low-Risk Basal Cell Carcinoma Lesions
-
Pulse Biosciences Announces FDA 510(k) Clearance for the Treatment of Sebaceous Hyperplasia
-
Pulse Biosciences Announces Strategic Change of Focus in Support of Significant Additional Opportunities for medicinal related Nano-Pulse Stimulation
-
Pulse Biosciences Reports Second Quarter 2022 Financial Results
-
Pulse Biosciences Receives FDA 510(k) Clearance of Expanded Energy Settings for use with the CellFX® System
-
Pulse Biosciences Schedules Second Quarter 2022 Financial Results Conference Call for August 10, 2022
-
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Pulse Biosciences, Inc. Announces the Closing of Its Rights Offering
-
Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering
-
Pulse Biosciences, Inc. Announces Changes to its Rights Offering
-
Pulse Biosciences Reports First Quarter 2022 Financial Results
-
Pulse Biosciences, Inc. Announces Commencement of Rights Offering
-
Pulse Biosciences Schedules First Quarter 2022 Financial Results Conference Call for May 11, 2022
-
Pulse Biosciences to Present New Data on Nano-Pulse Stimulation Procedure for Sebaceous Hyperplasia and for Focal Epithelial Hyperplasia at 2022 American Society of Laser Medicine and Surgery Annual C
-
Pulse Biosciences, Inc. Announces Rights Offering
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Acutus, Pulse, SunPower, and Butterfly and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Fennec, Astra, Acutus, and Pulse and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Pulse, SunPower, Butterfly, and GWG and Encourages Investors to Contact the Firm
Back to PLSE Stock Lookup
